AWARD-10 was a phase 3b, double-blind, parallel-arm, placebo-controlled, 24-week study on patients with inadequately controlled T2DM taking stable doses of an SGLT2 inhibitor with or without metformin. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.